The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of trifluridine/tipiracil in combination with irinotecan in patients with advanced gastric cancer refractory to fluoropyrimidine, platinum, and taxane.
 
Hiroki Hara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Lilly; MSD; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Takuro Mizukami
Honoraria - Asahi Kasei; Lilly Japan; Merck; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Keiko Minashi
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Takahashi
No Relationships to Disclose
 
Yusuke Amanuma
No Relationships to Disclose
 
Akio Nakasha
No Relationships to Disclose
 
Masaki Takahashi
No Relationships to Disclose
 
Takako Eguchi Nakajima
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Daiichi Sankyo; EPS Corporation; Kyowa Hakko Kirin; Lilly Japan; MERCK SERONO; MSD; Nippon Kayaku; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Research Funding - Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; ICON Clinical Research; Japan Clinical Research Operations; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; PAREXEL; PAREXEL; Sanofi; Taiho Pharmaceutical; Takeda